Previous 10 | Next 10 |
HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 at 10:40 a.m. Pacific Time (1:40 p.m. East...
2024-04-24 13:34:34 ET Summary Kiniksa Pharmaceuticals reported strong Q1 2024 results, with net sales of Arcalyst growing 85% YoY and 11% sequentially. Arcalyst's strong performance has driven a $10 million increase in the full-year net sales guidance range. Kiniksa plans to ...
2024-04-23 13:59:07 ET Kiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Conference Call April 23, 2024 8:30 AM ET Company Participants Rachel Frank - Associate Director of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Senior Vice Preside...
2024-04-23 07:37:59 ET More on Kiniksa Pharmaceuticals Seeking Alpha’s Quant Rating on Kiniksa Pharmaceuticals Historical earnings data for Kiniksa Pharmaceuticals Financial information for Kiniksa Pharmaceuticals Read the full article on Seeking Alp...
– ARCALYST ® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $370 - $390 million – – Abiprubart Phase 2b trial in Sjög...
Kiniksa Pharmaceuticals Ltd. (KNSA) is expected to report $-0.14 for Q1 2024 Agree Realty Corporation (ADC) is expected to report $1.01 for Q1 2024 1st Colonial Bancorp Inc (FCOB) is expected to report for Q1 2024 Equity Residential of Beneficial Interest (EQR) is expected to report $...
2024-04-22 17:05:04 ET More on Kiniksa Pharmaceuticals Kiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Kiniksa Pharmaceuticals Historical earnings data for Kiniksa Pharmaceuticals Financial informati...
HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:30 a.m. Eastern Time to report its first quarter 2024 financial results and recent portfolio ...
2024-04-02 22:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-23 21:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Kiniksa Pharmaceuticals Ltd. Company Name:
KNSA Stock Symbol:
NASDAQ Market:
Kiniksa Pharmaceuticals Ltd. Website:
LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 23, 2024 at 8:30 a.m. Eastern Time to report its second quarter 2024 financial results and recent portfolio...
– Abiprubart Phase 2b clinical trial in Sjögren’s Disease to evaluate treatment response across biweekly and monthly subcutaneous administrations – – Abiprubart clinical development in Sjögren’s Disease fully funded; company expects to r...
– Campaign to elevate experiences from the recurrent pericarditis community and provide resources to patients and caregivers – HAMILTON, Bermuda, June 24, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceu...